MediPharm Labs Reports First Quarter Results T.LABS | May 16, 2022 TORONTO, May 16, 2022 /PRNewswire/ -
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three months ended March 31, 2022.
MediPharm Labs Logo (CNW Group/MediPharm Labs Corp.)
Q1 2022 – Select Operating Highlights Continued leadership in global cannabis pharmaceuticals – poised to grow in U.S. market
In Q1, MediPharm entered the United States pharmaceutical market with the completion of the FDA Drug Master File (the "DMF") process for pure natural CBD APIs. A first for CBD by a Canadian company and the second natural CBD DMF at commercial scale in North America, the DMF allows for the registration of APIs with the FDA for commercial opportunities in pharmaceutical development, novel drugs, and generic drugs. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 20251.
News 
Market Data 
Discover 
